- Home
- SABR vs STTK Comparison
SABR vs STTK Comparison
Compare SABR & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | STTK |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 835.4M | 683.8M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SABR | STTK |
|---|---|---|
| Price | $2.21 | $7.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $1.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 3.9M | 1.3M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,866,956,000.00 | $1,000,000.00 |
| Revenue This Year | $7.51 | N/A |
| Revenue Next Year | $3.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $0.81 | $0.80 |
| 52 Week High | $2.30 | $8.33 |
Technical Indicators
Market Signals| Indicator | SABR | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 63.14 | 54.26 |
| Support Level | $1.58 | $5.87 |
| Resistance Level | N/A | $7.75 |
| Average True Range (ATR) | 0.16 | 0.52 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 87.20 | 55.08 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.